While the discovery of ESR1 mutations offers valuable insights into the evolution of breast tumors under the selective pressure of therapy, only a fraction of breast cancer patients with endocrine-resistant tumors harbors these mutations. The gene discussed is ESR1; the disease is breast cancer.